Epidermal growth factor receptor‑targeted antibody nimotuzumab combined with chemoradiotherapy improves survival in patients with locally advanced head and neck squamous cell carcinoma: a propensity score matching real-world study

Abstract

Patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) have poor survival outcomes. The real-world efficacy of nimotuzumab plus intensity modulated radiotherapy (IMRT)-based chemoradiotherapy in patients with LA-HNSCC remains unclear. A total of 25,442 HNSCC patients were screened, and 612 patients were matched by propensity score matching (PSM) (1:1). PSM was utilized to balance known confounding factors. Patients who completed at least five doses of nimotuzumab were identified as study group. The primary end point was 3-year overall survival (OS) rate. Log-rank test examined the difference between two survival curves and Cloglog transformation test was performed to compare survival at a fixed time point. The median follow-up time was 54.2 (95% confidence interval [CI]: 52.7–55.9) months. The study group was associated with improved OS (hazard ratio [HR] = 0.75, 95% CI: 0.57–0.99, p = 0.038) and progression-free survival (PFS) (HR = 0.74, 95% CI: 0.58–0.96, p = 0.021). Subgroup analysis revealed that aged 50–60 year, IV, N2, radiotherapy dose ≥ 60 Gy, without previous surgery, and neoadjuvant therapy have a trend of survival benefit with nimotuzumab. Nimotuzumab showed favorable safety, only 0.2% had nimotuzumab-related severe adverse events. Our study indicated the nimotuzumab plus chemoradiotherapy provides survival benefits and safety for LA-HNSCC patients in an IMRT era.

Keywords

chemoradiotherapy / IMRT / LA-HNSCC / nimotuzumab / safety / survival benefits

References

1	F Bray, J Ferlay, I Soerjomataram, RL Siegel, LA Torre, A Jemal. Global cancer statistics 2018: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2	MD Mody, JW Rocco, SS Yom, RI Haddad, NF Saba. Head and neck cancer. Lancet. 2021;398(10318):2289-2299.
3	C Maomao, L He, S Dianqin, et al. Current cancer burden in China: epidemiology, etiology, and prevention. Cancer Biol Med. 2022;19(8):1121-1138.
4	CR Leemans, PJF Snijders, RH Brakenhoff. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269-282.
5	DE Johnson, B Burtness, CR Leemans, VWY Lui, JE Bauman, JR Grandis. Head and neck squamous cell carcinoma head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92.
6	LQM Chow. Head and neck cancer. N Engl J Med. 2020;382(1):60-72.
7	JD Cramer, B Burtness, QT Le, RL Ferris. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669-683.
8	MK Ang, JE Montoya, E Tharavichitkul, et al. Phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. Head Neck. 2021;43(5):1641-1651.
9	LG Marcu, DC Marcu. Current omics trends in personalised head and neck cancer chemoradiotherapy. J Pers Med. 2021;11(11):1094.
10	Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576-582.
11	B Peltanova, M Raudenska, M Masarik. Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Mol Cancer. 2019;18(1):63.
12	AK Hess, A Müer, FD Mairinger, et al. MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. Eur J Cancer. 2017;77:3-12.
13	T Soonthornthum, H Arias-Pulido, N Joste, et al. Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol. 2011;22(10):2166-2178.
14	Y Liang, T Zhang, J Zhang. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: their relevance for cancer therapy. Pharmacol Res. 2020;161:105164.
15	L González, ME Díaz, JG Miquet, AI Sotelo, FP Dominici. Growth hormone modulation of hepatic epidermal growth factor receptor signaling. Trends Endocrinol Metab. 2021;32(6):403-414.
16	Z Li, DR Tyrpak, M Park, CT Okamoto, JA MacKay. A new temperature-dependent strategy to modulate the epidermal growth factor receptor. Biomaterials. 2018;183:319-330.
17	PE Dubé, F Yan, S Punit, et al. Epidermal growth factor receptor inhibits colitis-associated cancer in mice. J Clin Invest. 2012;122(8):2780-2792.
18	Q Li, Y Tie, A Alu, X Ma, H Shi. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduct Target Ther. 2023;8(1):31.
19	M Schrevel, A Gorter, SM Kolkman-Uljee, JB Trimbos, GJ Fleuren, ES Jordanova. Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer. Mod Pathol. 2011;24(5):720-728.
20	LR Harskamp, RT Gansevoort, H van Goor, E Meijer. The epidermal growth factor receptor pathway in chronic kidney diseases. Nat Rev Nephrol. 2016;12(8):496-506.
21	RI Nicholson, JM Gee, ME Harper. EGFR and cancer prognosis. Eur J Cancer. 2001;37(4):S9-S15. Suppl.
22	MJ Jelinek, EE Vokes. Epidermal growth factor receptor blockade in head and neck cancer: what remains? J Clin Oncol. 2019;37(31):2807-2814.
23	LF Chen, EE Cohen, JR Grandis. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010;16(9):2489-2495.
24	U Bartels, J Wolff, L Gore, et al. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol. 2014;16(11):1554-1559.
25	G de Castro Junior, JG Segalla, SJ de Azevedo, et al. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: nICE trial. Eur J Cancer. 2018;88:21-30.
26	B Schultheis, D Reuter, MP Ebert, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Ann Oncol. 2017;28(10):2429-2435.
27	T Crombet Ramos, B Mestre Fernández, Z Mazorra Herrera, NE Iznaga Escobar. Nimotuzumab for patients with inoperable cancer of the head and neck. Front Oncol. 2020;10:817.
28	U Bode, M Massimino, F Bach, et al. Nimotuzumab treatment of malignant gliomas. Expert Opin Biol Ther. 2012;12(12):1649-1659.
29	A Talavera, R Friemann, S Gómez-Puerta, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009;69(14):5851-5859.
30	VM Patil, V Noronha, A Joshi, et al. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer. 2019;125(18):3184-3197.
31	Q Wu, C Zhu, S Zhang, Y Zhou, Y Zhong. Hematological toxicities of concurrent chemoradiotherapies in head and neck cancers: comparison among cisplatin, nedaplatin, lobaplatin, and nimotuzumab. Original Research. 2021;11:762366.
32	BK Reddy, V Lokesh, MS Vidyasagar, et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol. 2014;50(5):498-505.
33	WK Boland, G Bebb. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther. 2009;9(9):1199-1206.
34	Z Mazorra, L Chao, A Lavastida, et al. Nimotuzumab: beyond the EGFR signaling cascade inhibition. Semin Oncol. 2018;45(1-2):18-26.
35	S Qi, Y Mao, M Jiang. A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer. Cancer Chemother Pharmacol. 2019;84(5):1115-1123.
36	Z Chen, Q Xue, X Chen, et al. Short-term efficacy and toxicity of Nimotuzumab combined with simultaneous integrated boost intensity-modulated radiotherapy for locally advanced esophageal cancer]. Zhonghua Yi Xue Za Zhi. 2016;96(8):640-642.
37	S González Fernández, Y Amador García, LG Boris Porras, et al. Nimotuzumab in the treatment of inoperable esophageal tumors of epithelial origin. J Oncol. 2022;2022:4128946.
38	HM Li, P Li, YJ Qian, et al. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma. BMC Cancer. 2016;16(1):946.
39	MO Rodríguez, TC Rivero R del Castillo Bahi, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 2010;9(5):343-349.
40	J Hu, Z Chen, J Lv, et al. The application of nimotuzumab combined with definitive chemoradiotherapy toward the treatment of locally advanced cervical esophageal carcinoma: a retrospective study. Front Oncol. 2022;12:905422.
41	AL Agero, SW Dusza, C Benvenuto-Andrade, KJ Busam, P Myskowski, AC Halpern. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55(4):657-670.
42	KK Ang, Q Zhang, DI Rosenthal, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: rTOG 0522. J Clin Oncol. 2014;32(27):2940-2950.
43	JA Bonner, PM Harari, J Giralt, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578.
44	G Garrido, IA Tikhomirov, A Rabasa, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 2011;11(4):373-382.
45	F Wang, C Jiang, Z Ye, et al. Efficacy and safety of nimotuzumab plus radiotherapy with or without cisplatin-based chemotherapy in an elderly patient subgroup (aged 60 and older) with nasopharyngeal carcinoma. Transl Oncol. 2018;11(2):338-345.
46	S Subramanian, S Nithya, S Chaudhari. Long term efficacy and safety of nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: a real world Indian experience. J Clin Oncol. 2018;36(15):e18077-e18077.